Global Cancer Diagnostics Market – Industry Trends - Forecast to 2026

  • Medical Devices
  • Publish Reports
  • Mar 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Cancer Diagnostics Market By Technology (Instrument Based, Platform-Based, Tumor Biomarker Tests), Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Pancreatic Cancer, Ovarian Cancer, Others), End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Market Analysis: Global Cancer Diagnostics Market

Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026, registering a CAGR of 6.84% in the forecast period of 2019-2026. This rise in market value can be attributed to innovations and advancements in technological offerings by the major manufacturers.

Market Definition: Global Cancer Diagnostics Market

Cancer diagnostics is the process of detecting various biomarkers, proteins and certain symptoms that result in the detection of presence of cancerous tumor in the patients. The detection of certain biomarkers and proteins that are prevalent in cancer disorders thereby result in the diagnosis process. The process of detecting cancer includes usage of certain technology and devices specifically used in its diagnosis.

Market Drivers

  • Significant contribution and investments undertaken by various organizations; this factor is expected to act as a driver for the market growth
  • Increasing levels of geriatric population along with the growth in prevalence of cancer; this factor is expected to act as a driver for the market growth

Market Restraints

  • High cost of diagnostics procedure for cancers available in the market is expected to act as a restraint to the market growth
  • Presence of strict regulations and standards for the approval and commercialization of cancer diagnostic products & services; this factor is expected to act as a restraint to the market growth

Segmentation: Global Cancer Diagnostics Market

  • By Technology

    • Instrument Based

      • Biopsies

        • Needle Biopsy
        • Endoscopic Biopsy
        • Bone Marrow Biopsy
        • Others

      • Liquid Biopsy

        • Diagnostic Imaging
        • Mammography
        • Ultrasound
        • Magnetic Resonance Imaging (MRI)
        • Computed Tomography (CT)
        • Positron Emission Tomography

          • Standalone Positron Emission Tomography
          • Hybrid Position Emission Tomography

    • Platform-Based

      • Immunohistochemistry (IHC)
      • Flow Cytometry
      • In-Situ Hybridization (ISH)
      • Polymerase Chain Reaction (PCR)
      • Next Generation Sequencing (NGS)
      • Microarrays
      • Others

    • Tumor Biomarker Tests

      • Alpha-Fetoprotein (AFP) Tests
      • CA-19 Radioimmunoassay Tests
      • BRCA Tests
      • ALK Tests
      • Carcinoembryonic Antigen (CEA) Tests
      • KRAS Mutation Tests
      • HER2 Tests
      • EGFR Mutation Tests
      • Circulating Tumor Cells (CTC) Tests
      • Prostate-Specific Antigen (PSA) Tests
      • Others

  • By Application

    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Lung Cancer
    • Prostate Cancer
    • Skin Cancer
    • Blood Cancer
    • Kidney Cancer
    • Pancreatic Cancer
    • Ovarian Cancer
    • Others

  • By End-User

    • Cancer Research Institutes
    • Diagnostic Laboratories
    • Hospitals
    • Others

  • By Geography

    • North America

      • US.
      • Canada
      • Mexico

    • South America

      • Brazil
      • Argentina
      • Rest of South America

    • Europe

      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe

    • Asia-Pacific

      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Thailand
      • Malaysia
      • Indonesia
      • Philippines
      • Rest of Asia Pacific

    • Middle East & Africa

      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East & Africa

Key Developments in the Market:

  • In March 2019, NeoGenomics Laboratories, Inc. announced the launch of “Ventana PD-L1 (SP142) Assay” testing for tumor tissue testing in patients with triple negative subtype of breast cancer. The test recently approved by the FDA for patients who might respond to “TECENTRIQ”, an immune checkpoint inhibitor in combination with chemotherapy.
  • In December 2018, QIAGEN and NeoGenomics Laboratories, Inc. announced that they had collaborated for the development and commercialization of diagnostic systems for cancer treatments. The agreement gives for the provision of QIAGEN companion diagnostics for the usage in clinical trials approval of oncology treatments until they are approved by the U.S. FDA.
  • In October 2018, Telerad Tech announced the launch of a new AI-based breast cancer detection system, “MammoAssist” for the detection of early stage cancer. The system analyses the mammogram results and images and detects the characteristics highlighted in breast cancers.
  • In August 2018, BioGenex announced the launch of five new antibodies for usage in cancer immunohistochemistry (IHC). The company’s IHC solution is capable of offering the widest portfolio inclusive of around 400 antibodies, reagents, consumables and ancillaries.

Competitive Analysis:

Global cancer diagnostics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cancer diagnostics market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Abbott; Agilent Technologies, Inc.; BD; bioMérieux SA; NeoGenomics Laboratories, Inc.; Telerad Tech; F. Hoffmann-La Roche Ltd; GENERAL ELECTRIC COMPANY; Hologic Inc.; Illumina, Inc.; QIAGEN; BioGenex; Siemens Healthcare GmbH; BioNTech Diagnostics GmbH; Thermo Fisher Scientific Inc.; Koninklijke Philips N.V.; are few of the major competitors currently present in the market.

Research Methodology: Global Cancer Diagnostics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global cancer diagnostics market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

SKU-

TABLE OF CONTENTS : GLOBAL CANCER DIAGNOSTICS MARKET

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY 1.2. MARKET DEFINITION 1.3. OVERVIEW OF GLOBAL CANCER DIAGNOSTICS MARKET 1.4. CURRENCY AND PRICING 1.5. LIMITATION 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED 2.2. GEOGRAPHIC SCOPE 2.3. YEARS CONSIDERED FOR THE STUDY 2.4. CURRENCY AND PRICING 2.5. RESEARCH METHODOLOGY 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.7. SECONDARY SOURCES 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. GROWTH OF AGING POPULATION AND RISING PREVALENCE OF CANCER 3.1.2. GOVERNMENT INITIATIVES FOR FUNDING AND AWARENESS ABOUT CANCER 3.1.3. KEY PLAYERS FOCUSING ON STRATEGIC DECISIONS TO GAIN MARKET SHARE 3.1.4. INCREASING PREVELANCE OF CANCER

3.2. RESTRAINTS

3.2.1. STRINGENT REULATIONS IMPOSED BY INTERNATIONAL AND LOCAL AUTHORITIES 3.2.2. SHORTAGE OF SKILLED AND TRAINED PROFESSIONALS

3.3. OPPORTUNITIES

3.3.1. NANOTECHNOLOGY: FORTHCOMING REVOLUTION IN CANCER DIAGNOSIS 3.3.2. ARTIFICIAL INTELLIGENCE AND THE IMMINENT HEALTH REVOLUTION 3.3.3. GROWING MEDICAL TOURISM IN ASIA

3.4. CHALLENGES

3.4.1. INCREASING RIVALRY AMONG THE COMPETITORS 3.4.2. POOR ACCESS TO CANCER DETECTION AND HIGH TREATMENT COCTS IN LOWER INCOME COUNTRIES

4. PREMIUM INSIGHTS 5. EXECUTIVE SUMMARY 6. GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1. OVERVIEW

6.2. PLATFORM BASED

6.2.1. POLYMERASE CHAIN REACTION(PCR) 6.2.2. IN SITU HYBRIDIZATION (ISH) 6.2.3. IMMUNOHISTOCHEMISTRY(IHC) 6.2.4. NEXT GENERATION SEQUENCING (NGS) 6.2.5. DNA MICROARRAYS 6.2.6. FLOW CYTOMETRY

6.3. INSTRUMENT BASED

6.3.1. IMAGING 6.3.1.1. MAGENTIC RESONANCE IMAGING (MRI) 6.3.1.2. CT(COMPUTED TOMOGRAPHY) 6.3.1.3. POSITRON EMISSION TOMOGRAPHY- COMPUTED TOMOGRAPHY (PET-CT) 6.3.1.4. MAMMOGRAPHY 6.3.1.5. ULTRASOUND 6.3.2. BIOPSY

7. GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION

7.1. OVERVIEW 7.2. LUNG CANCER 7.3. BREAST CANCER 7.4. COLORECTAL CANCER 7.5. MELANOMA 7.6. OTHERS

8. GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.2. NORTH AMERICA CANCER DIAGNOSTICS MARKET

8.2.1. U.S.CANCER DIAGNOSTICS MARKET 8.2.2. CANADA CANCER DIAGNOSTICS MARKET 8.2.3. MEXICO CANCER DIAGNOSTICS MARKET

8.3. EUROPE CANCER DIAGNOSTICS MARKET

8.3.1. GERMANY CANCER DIAGNOSTICS MARKET 8.3.2. FRANCE CANCER DIAGNOSTICS MARKET 8.3.3. U.K. CANCER DIAGNOSTICS MARKET 8.3.4. ITALY CANCER DIAGNOSTICS MARKET 8.3.5. SPAIN CANCER DIAGNOSTICS MARKET 8.3.6. RUSSIA CANCER DIAGNOSTICS MARKET 8.3.7. TURKEY CANCER DIAGNOSTICS MARKET 8.3.8. BELGIUM CANCER DIAGNOSTICS MARKET 8.3.9. NETHERLANDS CANCER DIAGNOSTICS MARKET 8.3.10. SWITZERLAND CANCER DIAGNOSTICS MARKET 8.3.11. REST OF EUROPE CANCER DIAGNOSTICS MARKET

8.4. APAC CANCER DIAGNOSTICS MARKET

8.4.1. JAPAN CANCER DIAGNOSTICS MARKET 8.4.2. CHINA CANCER DIAGNOSTICS MARKET 8.4.3. INDIA CANCER DIAGNOSTICS MARKET 8.4.4. SOUTH KOREA CANCER DIAGNOSTICS MARKET 8.4.5. AUSTRALIA CANCER DIAGNOSTICS MARKET 8.4.6. THAILAND CANCER DIAGNOSTICS MARKET 8.4.7. SINGAPORE CANCER DIAGNOSTICS MARKET 8.4.8. MALAYSIA CANCER DIAGNOSTICS MARKET 8.4.9. INDONESIA CANCER DIAGNOSTICS MARKET 8.4.10. PHILIPPINES CANCER DIAGNOSTICS MARKET 8.4.11. REST OF APAC CANCER DIAGNOSTICS MARKET

8.5. SOUTH AMERICA CANCER DIAGNOSTICS MARKET

8.5.1. BRAZIL CANCER DIAGNOSTICS MARKET 8.5.2. REST OF SOUTH AMERICA CANCER DIAGNOSTICS MARKET 8.6. MEA CANCER DIAGNOSTICS MARKET 8.6.1. SOUTH AFRICA CANCER DIAGNOSTICS MARKET 8.6.2. REST OF MEA CANCER DIAGNOSTICS MARKET

9. GLOBAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

9.1. COMPANY SHARE ANALYSIS: GLOBAL CANCER DIAGNOSTICS IMAGING MARKET 9.2. COMPANY SHARE ANALYSIS: GLOBAL CANCER DIAGNOSTICS PLATFORM BASED MARKET

10. COMPANY PROFILES

10.1. C. R. BARD, INC.

10.1.1. COMPANY OVERVIEW 10.1.2. REVENUE ANALYSIS 10.1.3. PRODUCT PORTFOLIO 10.1.4. RECENT DEVELOPMENTS

10.2. ILLUMINA, INC.

10.2.1. COMPANY OVERVIEW 10.2.2. REVENUE ANALYSIS 10.2.3. RECENT DEVELOPMENTS 10.2.4. PRODUCT PORTFOLIO

10.3. QIAGEN

10.3.1. COMPANY OVERVIEW 10.3.2. REVENUE ANALYSIS 10.3.3. RECENT DEVELOPMENTS 10.3.4. PRODUCT PORTFOLIO

10.4. ABBOTT

10.4.1. COMPANY OVERVIEW 10.4.2. REVENUE ANALYSIS 10.4.3. RECENT DEVELOPMENTS 10.4.4. PRODUCT PORTFOLIO

10.5. SIEMENS HEALTHCARE GMBH

10.5.1. COMPANY OVERVIEW 10.5.2. REVENUE ANALYSIS 10.5.3. RECENT DEVELOPMENTS 10.5.4. PRODUCT PORTFOLIO

10.6. AGILENT TECHNOLOGIES

10.6.1. COMPANY OVERVIEW 10.6.2. REVENUE ANALYSIS 10.6.3. PRODUCT PORTFOLIO 10.6.4. RECENT DEVELOPMENTS

10.7. THERMO FISHER SCIENTIFIC INC.

10.7.1. COMPANY OVERVIEW 10.7.2. REVENUE ANALYSIS 10.7.3. PRODUCT PORTFOLIO 10.7.4. RECENT DEVELOPMENTS

10.8. BECTON, DICKINSON AND COMPANY

10.8.1. COMPANY OVERVIEW 10.8.2. REVENUE ANALYSIS 10.8.3. PRODUCT PORTFOLIO 10.8.4. RECENT DEVELOPMENTS

10.9. GE HEALTHCARE

10.9.1. COMPANY OVERVIEW 10.9.2. REVENUE ANALYSIS 10.9.3. PRODUCT PORTFOLIO 10.9.4. RECENT DEVELOPMENTS

10.10. F. HOFFMANN-LA ROCHE LTD

10.10.1. COMPANY OVERVIEW 10.10.2. REVENUE ANALYSIS 10.10.3. PRODUCT PORTFOLIO 10.10.4. RECENT DEVELOPMENTS

10.11. HOLOGIC INC.

10.11.1. COMPANY OVERVIEW 10.11.2. REVENUE ANALYSIS 10.11.3. RECENT DEVELOPMENTS 10.11.4. PRODUCT PORTFOLIO

10.12. KONINKLIJHE PHILIPS N.V.

10.12.1. COMPANY OVERVIEW 10.12.2. REVENUE ANALYSIS 10.12.3. PRODUCT PORTFOLIO 10.12.4. RECENT DEVELOPMENTS

11. RELATED REPORTS

LIST OF TABLE : GLOBAL CANCER DIAGNOSTICS MARKET

TABLE 1 GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 2 GLOBAL PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 3 GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 4 GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 5 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 6 GLOBAL NEXT GENERATION SEQUENCING MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 7 GLOBAL DNA MICROARRAYS MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 8 GLOBAL FLOW CYTOMETRY MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 9 GLOBAL INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 10 GLOBAL INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING BY REGION, 2015– 2024 (USD MILLION) TABLE 11 GLOBAL INSTRUMENT BASED CNACER DIAGNOSTICS MARKET, BY BIOPSY , BY REGION, 2015– 2024 (USD MILLION) TABLE 12 GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION) TABLE 13 WORLDWIDE LUNG CANCER INCIDENCES TABLE 14 GLOBAL CANCER DIAGNOSTICS MARKET, LUNG CANCER, BYREGION, 2015 – 2024 (USD MILLION) TABLE 15 WORLDWIDE BREAST CANCER INCIDENCES TABLE 16 GLOBAL CANCER DIAGNOSTICS MARKET, BY BREAST CANCER, BY REGION, 2015 – 2024 (USD MILLION) TABLE 17 WORLDWIDE COLORECTAL CANCER INCIDENCES TABLE 18 GLOBAL CANCER DIAGNOSTICS MARKET, BY COLORECTAL CANCER, BY REGION, 2015 – 2024 (USD MILLION) TABLE 19 WORLDWIDE MELANOMA CANCER INCIDENCES TABLE 20 GLOBAL CANCER DIAGNOSTICS MARKET, BY MELANOMA , BY REGION2015 – 2024 (USD MILLION) TABLE 21 ESTIMATED NEW CASES OF CANCER IN 2017 TABLE 22 GLOBAL CANCER DIAGNOSTICS MARKET, BY OTHERS, BY REGION, 2015 – 2024 (USD MILLION) TABLE 23 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, 2015 – 2024 (USD MILLION) TABLE 24 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 25 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 26 NORTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 27 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 28 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 29 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 30 U.S.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 31 U.S. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 32 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 33 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 34 U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 35 CANADA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 36 CANADA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 37 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 38 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 39 CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 40 MEXICO CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 41 MEXICO PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 42 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 43 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 44 MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 45 EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024(USD MILLION) TABLE 46 EUROPE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 47 EUROPE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 48 EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 49 EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 50 EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 51 GERMANY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 52 GERMANY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 53 GERMANY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 54 GERMANY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 55 GERMANY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 56 FRANCE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 57 FRANCE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 58 FRANCE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 59 FRANCE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 60 FRANCE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 61 U.K.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 62 U.K. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 63 U.K. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 64 U.K. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 65 U.K. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 66 ITALY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 67 ITALY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 68 ITALY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 69 ITALY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 70 ITALY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 71 SPAIN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 72 SPAIN PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 73 SPAIN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 74 SPAIN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 75 SPAIN CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 76 RUSSIA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 77 RUSSIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 78 RUSSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 79 RUSSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 80 RUSSIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 81 TURKEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 82 TURKEY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 83 TURKEY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 84 TURKEY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 85 TURKEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 86 BELGIUM CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 87 BELGIUM PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 88 BELGIUM INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 89 BELGIUM INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 90 BELGIUM CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 91 NETHERLANDSCANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 92 NETHERLANDS PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 93 NETHERLANDS INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 94 NETHERLANDS INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 95 NETHERLANDS CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 96 SWITZERLAND CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 97 SWITZERLAND PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 98 SWITZERLAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 99 SWITZERLAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 100 SWITZERLAND CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 101 REST OF EUROPECANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 102 REST OF EUROPE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 103 REST OF EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 104 REST OF EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 105 REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 106 APAC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 107 APAC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 108 APAC PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 109 APAC INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 110 APAC INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 111 APAC CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 112 JAPANCANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 113 JAPAN PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 114 JAPAN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 115 JAPAN INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 116 JAPAN CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 117 CHINA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 118 CHINA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 119 CHINA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 120 CHINA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 121 CHINA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 122 INDIACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 123 INDIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 124 INDIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 125 INDIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 126 INDIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 127 SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 128 SOUTH KOREA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 129 SOUTH KOREA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 130 SOUTH KOREA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 131 SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 132 AUSTRALIACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 133 AUSTRALIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 134 AUSTRALIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 135 AUSTRALIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 136 AUSTRALIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 137 THAILAND CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 138 THAILAND PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 139 THAILAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 140 THAILAND INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 141 THAILAND CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 142 SINGAPORE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 143 SINGAPORE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 144 SINGAPORE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 145 SINGAPORE INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 146 SINGAPORE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 147 MALAYSIA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 148 MALAYSIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 149 MALAYSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 150 MALAYSIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 151 MALAYSIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 152 INDONESIA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 153 INDONESIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 154 INDONESIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 155 INDONESIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 156 INDONESIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 157 PHILIPPINES CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 158 PHILLIPINES PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 159 PHILIPPINES INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 160 PHILIPPINES INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 161 PHILIPPINES CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 162 REST OF APAC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 163 REST OF APAC PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 164 REST OF APAC INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 165 REST OF APAC INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 166 REST OF APAC CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 167 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 168 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 169 SOUTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 170 SOUTH AMERICA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 171 SOUTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 172 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 173 BRAZIL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 174 BRAZIL PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 175 BRAZIL INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 176 BRAZIL INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 177 BRAZIL CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 178 REST OF SOUTH AMERICACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 179 REST OF SOUTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 180 REST OF SOUTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 181 REST OF SOUTH AMERICA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 182 REST OF SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 183 MEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 184 MEA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 185 MEA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 186 MEA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 187 MEA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 188 MEA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 189 SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 190 SOUTH AFRICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 191 SOUTH AFRICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 192 SOUTH AFRICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 193 SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 194 REST OF MEACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

LIST OF FIGURES : GLOBAL CANCER DIAGNOSTICS MARKET

FIGURE 1 GLOBAL CANCER DIAGNOSTICS MARKET: SEGMENTATIO FIGURE 2 GLOBAL CANCER DIAGNOSTICS MARKET: GEOGRAHIC SCOP FIGURE 3 GLOBAL CANCER DIAGNOSTICS MARKET: DATA TRIANGULATIO FIGURE 4 GLOBAL CANCER DIAGNOSTICS MARKET: SNAPSHOT FIGURE 5 GLOBAL CANCER DIAGNOSTICS MARKET: BOTTOM UP APPROACH FIGURE 6 GLOBAL CANCER DIAGNOSTICS MARKET: TOP DOWN APPROACH FIGURE 7 GLOBAL CANCER DIAGNOSTICS MARKET: INTERVIEWS BY REGION AND DESIGNATION FIGURE 8 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE CANCER DIAGNOSTICS MARKET FIGURE 9 POPULATION AGED OVER 60 (MILLIONS) (2010 VS 2050) FIGURE 10 TECHNOLOGICAL ADVANCEMENTS IN THE DIAGNOSTICS IMAGING SYSTEMS AND GROWING NUMBER OF CANCER PATIENTS IS EXPECTED TO DRIVE THE MARKET FOR CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD 2017 TO 2024 FIGURE 11 INSTRUMENT BASED MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER DIAGNOSTICS MARKET IN 2017 FIGURE 12 ASIA-PACIFIC AND SOUTH AMERICA ARE THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR CANCER DIAGNOSTICS MANUFACTURERS IN THE FORECAST PERIOD 2017 TO 2024 FIGURE 13 NORTH AMERICA DOMINATES THE MARKET FOR CANCER DIAGNOSTICS IN 2016 AND IS EXPECTED TO CONTINUE THIS TREND IN THE FORECAST PERIOD TO 2024 FIGURE 14 GLOBAL CANCER DIAGNOSTICS MARKET,SEGMENTATION: BY TECHNNOLOGY FIGURE 15 GLOBAL CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, SNAPSHOT 2016 FIGURE 16 GLOBAL CANCER DIAGNOSTICSMARKET: BY APPLICATION, SNAPSHOT 2016 FIGURE 17 NORTH AMERICA CANCER DIAGNOSTICS MARKET SNAPSHOT (2017) FIGURE 18 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016) FIGURE 19 NORTH AMERICA CANCER DIAGNOSTICS MARKET : BY COUNTRY (2017) FIGURE 20 NORTH AMERICA CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024) FIGURE 21 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2017 & 2024) FIGURE 22 EUROPEAN UNION POPULATION AGES 65 AND ABOVE (% OF TOTAL) FIGURE 23 EUROPE CANCER DIAGNOSTICS MARKET SNAPSHOT (2017) FIGURE 24 EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016) FIGURE 25 EUROPE CANCER DIAGNOSTICS MARKET BY COUNTRY (2017) FIGURE 26 EUROPE CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024) FIGURE 27 EUROPE CANCER DIAGNOSTICS MARKET BY TECHNOLOGY (2017 & 2024) FIGURE 28 APAC CANCER DIAGNOSTICS MARKET : SNAPSHOT (2017) FIGURE 29 APAC CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016) FIGURE 30 APAC CANCER DIAGNOSTICS MARKET : BY COUNTRY (2017) FIGURE 31 APAC CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024) FIGURE 32 APAC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2017 & 2024) FIGURE 33 SOUTH AMERICA CANCER DIAGNOSTICS MARKET SNAPSHOT (2017) FIGURE 34 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016) FIGURE 35 SOUTH AMERICA CANCER DIAGNOSTICS MARKET : BY COUNTRY (2017) FIGURE 36 SOUTH AMERICA CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024) FIGURE 37 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2017 & 2024) FIGURE 38 MEA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2017) FIGURE 39 MEA CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016) FIGURE 40 MEA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2017) FIGURE 41 MEA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2016 & 2024) FIGURE 42 MEA CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY (2016 & 2024) FIGURE 43 GLOBAL CANCER DIAGNOSTICS MARKET: BY IMAGING, COMPANY SHARE 2016 (%) FIGURE 44 GLOBAL CANCER DIAGNOSTICS MARKET: BY PLATFORM BASED, COMPANY SHARE 2016 (%)

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART